Skip to main content
Gennex Laboratories Ltd logo

Gennex Laboratories Ltd — Investor Relations & Filings

Ticker · 531739 ISIN · INE509C01026 LEI · 335800IFCLCYQKPK7D27 BSE.NS Manufacturing
Open in API
Filings indexed 8 across all filing types
Latest filing 2026-05-30 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS 531739

About Gennex Laboratories Ltd

https://www.gennexlab.com

Gennex Laboratories Ltd specializes in the manufacturing and distribution of Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates. The organization operates manufacturing facilities dedicated to producing high-quality chemical compounds for the global healthcare market. Its core product portfolio includes therapeutic agents such as Guaifenesin, Methocarbamol, Phenylephrine Hydrochloride, and Fluconazole. The company emphasizes research and development to optimize chemical synthesis processes and ensure compliance with international regulatory standards. It serves a diverse clientele, including generic drug manufacturers and large-scale enterprises, providing essential components for respiratory, muscle relaxant, and antifungal medications. By maintaining a robust supply chain and focusing on process efficiency, the company supports the production of various medicinal formulations.

Recent filings

Filing Released Lang Actions
In just concluded Meeting of Board of Directors, the Board approved and considered the following items: 1. Audited Standalone & Consolidated Financial Results for the Quarter and Year ....
Interim / Quarterly Report Classification · 92% confidence The document is an exchange filing under SEBI LODR announcing the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. It includes full financial statements (P&L, balance sheet, cash flow statement) along with notes, not just summary highlights. This matches the definition of an Interim / Quarterly Report (IR) since it provides substantive financial data for a period shorter than a full fiscal year (quarter) and also the audited year‐end figures filed with stock exchanges, rather than a full annual report or mere earnings release. FY 2026
2026-05-30 English
In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Audited Standalone & Consolidated Financial results for the Quarter & Year Ended ....
Interim / Quarterly Report Classification · 80% confidence The document is a stock exchange filing under SEBI LODR Regulations 29, 33 & 47 notifying the outcome of the board meeting which approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. It includes full financial statements (P&L, balance sheet, cash flows, notes), so it is not merely a highlights‐only earnings release but a comprehensive results announcement for a period shorter than a full fiscal year (quarter) plus year‐end results. This matches the definition of an Interim / Quarterly Report (IR) rather than a simple Earnings Release or a full Annual Report. FY 2026
2026-05-30 English
In compliance with Regulation 24A of SEBI (LODR) Regulations, 2015, Board appointed M/s. Mohammed Tausif Shamim & Co., practicing Company Secretary, Kolkata as Secretarial Auditor of the ....
Regulatory Filings Classification · 95% confidence The document is a formal submission to multiple stock exchanges of the Annual Secretarial Compliance Report for the financial year ended March 31, 2026, prepared by a Practicing Company Secretary under SEBI (LODR) Regulations. It is not a financial results announcement, earnings transcript, management discussion, capital raising notice, or a proxy/materials for shareholder voting. It is a compliance report filed as per SEBI regulations, fitting the “Regulatory Filings” category (RNS) rather than a full financial audit report (10-K/IR/AR) or any other specialized filing. Therefore it should be classified as RNS.
2026-05-30 English
We refer to your email of 25th May, 2026 seeking clarification on your observation regarding significant movement noticed by the Exchange in the price of our company security at your exchange ....
Regulatory Filings Classification · 95% confidence The document is a formal letter under SEBI (LODR) Regulation 30, submitted to the exchange to clarify unusual price movements. It contains no financial statements or investor presentation materials, nor does it announce dividend, AGM materials, or management changes. It is a routine regulatory compliance announcement/clarification. Therefore, it best fits the generic Regulatory Filings category.
2026-05-26 English
Pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015, please fine enclosed herewith Newspaper Publication regarding Meeting of the Board of Directors of the Company Scheduled to be ....
Regulatory Filings Classification · 78% confidence The document is a compliance submission under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, notifying stock exchanges of a newspaper publication of a Board Meeting notice. It does not contain actual financial results or the full report itself, nor is it a management change, dividend notice, or AGM material. It is a general regulatory announcement falling under ‘Regulatory Filings’ (RNS).
2026-05-20 English
Gennex Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve With reference to the above ....
Regulatory Filings Classification · 84% confidence The document is an intimation to stock exchanges under SEBI (LODR) regulations announcing the date and agenda for a forthcoming Board of Directors meeting. It does not present any financial statements itself, nor does it detail board changes, dividends, or other specific report content. It is a regulatory announcement notifying compliance with listing regulations. This fits the fallback category for miscellaneous regulatory filings.
2026-05-19 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.